Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

267 Press Releases
DateTitleCompany
28 Jul 15 Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer Boehringer Ingelheim,
Published by
PharmiWeb.com
28 Jul 15 Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer Boehringer Ingelheim,
Published by
Business Wire
25 Jul 15 MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke Boehringer Ingelheim,
Published by
PharmiWeb.com
24 Jul 15 MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke Boehringer Ingelheim,
Published by
Business Wire
16 Jul 15 Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim,
Published by
PharmiWeb.com
15 Jul 15 Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim,
Published by
Business Wire
08 Jul 15 Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) Boehringer Ingelheim,
Published by
PharmiWeb.com
08 Jul 15 Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung Boehringer Ingelheim,
Published by
PharmiWeb.com
06 Jul 15 Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung Boehringer Ingelheim,
Published by
PharmiWeb.com
06 Jul 15 Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) (...) Boehringer Ingelheim,
Published by
Business Wire
02 Jul 15 New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries Boehringer Ingelheim,
Published by
PharmiWeb.com
02 Jul 15 New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries   Boehringer Ingelheim,
Published by
Business Wire
01 Jul 15 Boehringer Ingelheim Animal Health: 2015 European PRRS Research Award open for submissions until July 31st Boehringer Ingelheim,
Published by
PharmiWeb.com
22 Jun 15 Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study Boehringer Ingelheim,
Published by
PharmiWeb.com
22 Jun 15 Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study Boehringer Ingelheim,
Published by
Business Wire
16 Jun 15 New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers Boehringer Ingelheim,
Published by
PharmiWeb.com
16 Jun 15 New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers Boehringer Ingelheim GmbH,
Published by
Business Wire
08 Jun 15 Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA Boehringer Ingelheim,
Published by
PharmiWeb.com
08 Jun 15 Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care Boehringer Ingelheim,
Published by
PharmiWeb.com
08 Jun 15 Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care Boehringer Ingelheim,
Published by
Business Wire
08 Jun 15 Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA Boehringer Ingelheim,
Published by
Business Wire
03 Jun 15 NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication Boehringer Ingelheim,
Published by
Business Wire
02 Jun 15 Boehringer Ingelheim Statement on Proposed CT Tax Increases Boehringer Ingelheim,
Published by
Business Wire
02 Jun 15 Boehringer Ingelheim’s Vargatef?® (nintedanib) in combination with docetaxel is recommended as a treatment option within its marketing authorisation for patents with a common type of lung cancer Boehringer Ingelheim,
Published by
Business Wire
01 Jun 15 ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung Boehringer Ingelheim,
Published by
PharmiWeb.com
28 May 15 Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union Boehringer Ingelheim,
Published by
Business Wire
27 May 15 Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions Boehringer Ingelheim,
Published by
Business Wire
20 May 15 New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy123 Boehringer Ingelheim,
Published by
Business Wire
18 May 15 Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate Boehringer Ingelheim,
Published by
Business Wire
18 May 15 New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups Boehringer Ingelheim,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.